Keywords: bayer, settles, lipobay/baycol, cases, 1b, germany, says
Bayer settles 2,861 Lipobay/Baycol cases for $1.1B
Article | 27 September 2004
Germany's Bayer says it has settled over 2,800 cases regarding the withdrawal of its cholesterol-lowerer Lipobay/Baycol (cerivastatin) in 2001, for a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
